• Home
  1. Home
  2. Understanding the immunology of the Zostavax shingles vaccine
Scientific article
Review
English

Understanding the immunology of the Zostavax shingles vaccine

ContributorsSullivan, Nicole L; Eberhardt, Christiane Sigrid; Wieland, Andreas; Vora, Kalpit A; Pulendran, Bali; Ahmed, Rafi
Published inCurrent Opinion in Immunology, vol. 59, p. 25-30
Publication date2019
Abstract

Zostavax is a live-attenuated varicella zoster virus (VZV) vaccine recommended for use in adults >50 years of age to prevent shingles. The main risk factor for the development of shingles is age, which correlates with decreasing cell-mediated immunity. These data suggest a predominant role of T cell immunity in controlling VZV latency. However, other components of the immune system may also contribute. In this review, we will discuss how the immune system responds to Zostavax, focusing on recent studies examining innate immunity, transcriptomics, metabolomics, cellular, and humoral immunity.

Keywords
  • Age Factors
  • Chickenpox/immunology
  • Herpes Zoster/immunology/prevention & control
  • Herpes Zoster Vaccine/immunology
  • Herpesvirus 3
  • Human/physiology
  • Humans
  • Immunity
  • Cellular
  • Immunity
  • Humoral
  • Immunity
  • Innate
  • Middle Aged
  • T-Lymphocytes/immunology
  • Transcriptome
  • Vaccines
  • Attenuated
  • Virus Activation/immunology
  • Virus Latency/immunology
Affiliation entities
Research groups
Citation (ISO format)
SULLIVAN, Nicole L et al. Understanding the immunology of the Zostavax shingles vaccine. In: Current Opinion in Immunology, 2019, vol. 59, p. 25–30. doi: 10.1016/j.coi.2019.02.005
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0952-7915
298views
0downloads

Technical informations

Creation16/10/2020 14:21:00
First validation16/10/2020 14:21:00
Update15/03/2023 22:51:57
Status update15/03/2023 22:51:56
Last indexation31/10/2024 20:05:48
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack